Meeting Banner
Abstract #0930

MR elastography reveals a marked increase in breast cancer viscoelasticity in vivo following hyaluronan degradation by PEGPH20

Emma L. Reeves1, Jin Li1,2, Konstantinos Zormpas-Petridis1, Jessica K. R. Boult1, James Sullivan1,3, Craig Cummings1, Barbara Blouw4, David Kang4, Ralph Sinkus5, Yann Jamin1, Jeffrey C. Bamber1, and Simon P. Robinson1
1Radiotherapy & Imaging, Institute of Cancer Research, London, United Kingdom, 2Institutes of Brain Science, Fudan University, Shanghai, China, 3Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, 4Halozyme Therapeutics, San Diego, CA, United States, 5Division of Imaging Sciences and Biomedical Engineering, King's Health Partners, St Thomas's Hospital, London, United Kingdom

We hypothesised that hyaluronan (HA) degradation by PEGPH20 may alter tumour viscoelasticity measured by MR elastography (MRE). MRE was performed before and after PEGPH20 in three orthotopic breast tumour models (4T1, 4T1/HAS3 and MDA-MB-231 LM2-4). Viscoelastic properties did not change following PEGPH20 in 4T1 and 4T1/HAS3 tumours. However, a dramatic PEGPH20-induced increase in tumour viscoelasticity was seen in MDA-MB-231 LM2-4 tumours, likely the result of collagen network rearrangement and not HA degradation alone. Although MRE is unlikely to provide a robust biomarker of PEGPH20 response, these data clearly demonstrate that MRE-derived biomarkers can inform on increased tumour stiffness in vivo.

This abstract and the presentation materials are available to members only; a login is required.

Join Here